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Autoimmune encephalitis (AIE) is a group of disorders in which autoantibodies directed
at antigens located on the plasma membrane of neurons induce severe neurological
symptoms. In contrast to classical paraneoplastic disorders, AIE patients respond well
to immunotherapy. The detection of neuronal surface autoantibodies in patients’ serum
or CSF therefore has serious consequences for the patients’ treatment and follow-
up and requires the availability of sensitive and specific diagnostic tests. This mini-
review provides a guideline for both diagnostic and research laboratories that work
on the detection of known surface autoantibodies and/or the identification of novel
surface antigens. We discuss the strengths and pitfalls of different techniques for anti-
neuronal antibody detection: (1) Immunohistochemistry (IHC) and immunofluorescence
on rat/primate brain sections; (2) Immunocytochemistry (ICC) of living cultured
hippocampal neurons; and (3) Cell Based Assay (CBA). In addition, we discuss the
use of immunoprecipitation and mass spectrometry analysis for the detection of novel
neuronal surface antigens, which is a crucial step in further disease classification and the
development of novel CBAs.
Keywords: autoantibodies, anti-neuronal antibodies, cell-surface antigens, diagnostic testing, autoimmune
encephalitis
INTRODUCTION
Anti-neuronal autoimmune encephalitis (AIE) is a heterogeneous group of disorders characterized
by autoantibodies that are directed at the extracellular domains of antigens in the synaptic or
extra-synaptic plasma membrane. These antigens are often key players in synaptic transmission
and neuronal excitability. Antibody binding to these antigens therefore directly leads to neuronal
dysfunction. When the antibodies are removed, neuronal dysfunction is commonly reversed and
patients often completely recover (van Coevorden-Hameete et al., 2014; Höftberger, 2015). This
striking response to immunotherapy stresses the importance of early diagnosis and treatment
of AIE. To achieve this, the availability of sensitive and specific tests to detect cell-surface
autoantibodies is of key importance.
Whereas diagnostics in AIE is an emerging field, large experience exists with
laboratory tests used for the detection of anti-neuronal antibodies in classical paraneoplastic
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neurological syndromes (PNS; Probst et al., 2014). Some, but
not all, of the methods used in PNS diagnostics are also
suitable to detect autoantibodies involved in AIE. The different
requirements for diagnostic methods are mainly determined
by two major differences between classical PNS antigens
and AIE antigens. Classical PNS antigens are primarily located
intracellular whereas AIE antigens are located in or on the plasma
membrane. In addition, antibodies directed at classical PNS
antigens are mostly recognizing linear epitopes, whereas surface
antigens contain mostly conformational epitopes.
Core methods in PNS and AIE diagnostics are
immunohistochemistry (IHC) on rat brain sections and
indirect immunofluorescence (IIF) on primate cerebellum
sections. In these assays all relevant antigens are present
and accessible. For the detection of neuronal surface
antigens also immunocytochemistry (ICC) of primary
hippocampal neurons is used. Although these techniques
are very useful as initial screening methods, they do not
allow for the identification of the exact molecular target of
the autoantibodies. In addition, these techniques require
extensive experience and are labor-intensive. Therefore,
for diagnostic purposes, highly specific confirmatory
tests are needed. For PNS antigens immunoblotting
with recombinant antigen is used most frequently as
a confirmatory test (Willison et al., 2000). For surface
antigens a radioimmunoassay (RIA) can be used to detect
antibodies directed at a channel complex, such as voltage
gated calcium channels (VGCC; Motomura et al., 1995).
However, a RIA cannot discriminate between antibodies
to different channel components that can be of clinical
relevance, as is the case for antibodies directed to the voltage
gated potassium channel (VGKC; Lai et al., 2010; Lancaster
et al., 2011a; van Sonderen et al., 2016b). To test single
neuronal surface antigens cell based assays (CBA) are the
method of choice. In CBAs the natural environment and
conformation of the antigen is mostly maintained (Willison
et al., 2000).
Despite the fact that many of these techniques are
currently used in AIE diagnostic and research laboratories,
the methodology to detect cell-surface antibodies is not widely
standardized. In this article we review the advantages and pitfalls
of three different techniques for antibody detection: (1) IHC/IIF
on adult rat/primate brain slices; (2) ICC on living cultured rat
hippocampal neurons; and (3) CBAs for neuronal membrane
proteins (for an overview see Table 1). In addition we evaluate
the use of immunoprecipitation and mass spectrometry analysis
for the identification of novel cell-surface antigens.
IMMUNOHISTOCHEMISTRY
The reactivity of antibodies present in patient serum or CSF
against rat brain proteins can be tested with IHC. In this assay
5–9 µm thick complete rat brain slices are used. Therefore all
possible antigens are available and accessible, and different brain
regions can be assessed. This technique has been a core method
for the detection of antibodies directed at intracellular antigens
in PNS. For classical PNS antigens diagnostic laboratories mostly
use IIF of primate cerebellum, for which a commercial kit is
available.
Although similar in many respects, the detection of synaptic
surface antibodies requires a different pre-treatment of the
rat brain tissue. For classical PNS antibodies brain tissue
is snapfrozen, sliced with a cryostat and subsequently fixed
with acetone or paraformaldehyde (PFA; Graus et al., 1997).
For cell-surface antigens rat brains are fixed with PFA for
1 h at 4◦C, cryoprotected in 40% sucrose for at least
24 h, snapfrozen in isopentane and subsequently sliced with
a cryostat (Ances et al., 2005; Dalmau et al., 2007). By
using this method of tissue preparation, antigens are well
preserved and no antigen retrieval methods need to be used
to obtain robust staining. The slices are incubated with
serum or CSF and bound antibodies can be visualized with
diaminobenzidine (DAB) peroxidase or fluorescently labeled
secondary antibodies. For classical PNS antibodies, generally
primate cerebellum is scored for specific staining patterns such as
the distinct punctate anti-Tr/delta/notch-like epidermal growth
factor-related receptor (DNER) pattern (Graus et al., 1997) or
nuclear staining of anti-Hu antibodies (Sillevis Smitt et al.,
2002). For cell-surface antigens, the hippocampus is scored for
staining of the synapses containing gray matter, termed neuropil
(Figure 1A). This neuropil staining is less robust when using
the classical PNS pre-treatment of rat brain tissue. The different
cell-surface antibodies can produce highly characteristic staining
patterns on rat hippocampus (Dalmau et al., 2008; Montojo et al.,
2015). With good quality IHC and experienced observers the
recognition of these specific staining patterns may already lead
to diagnosis.
Most synaptic proteins are highly homologous (for example
rat-human homology on protein level for the NR1 subunit of the
NMDA receptor (NMDAR) is 99.3% (source: NCBI). However,
when screening for novel neuronal antigens it is important to
keep in mind that due to interspecies differences some epitopes
might be absent in rodents and are therefore missed on IHC.
IMMUNOCYTOCHEMISTRY ON LIVING
PRIMARY HIPPOCAMPAL NEURONS
To assess antibody reactivity to extracellular epitopes live
staining of cultured primary rat hippocampal neurons with
patients’ serum or CSF can be performed. In theory, this way only
relevant extracellular epitopes will be detected, diminishing the
background signal. Also, the effects of the protein crosslinking
fixative PFA, on the antigenicity of the receptor will be
circumvented (Peränen et al., 1993).
For this assay it is important to use neurons that are more
than 14 days in culture and have developed axons and synapses.
Serum or CSF is applied when the neurons are alive and are
incubated for 30–45 min at 37◦C. The secondary antibody
can be applied on living neurons or after fixation under non-
permeabilizing conditions (Hughes et al., 2010). In both cases
only extracellular epitopes will be detected and result in a
punctate staining pattern along the neurites (Figure 1B). In
contrast with IHC, the staining patterns of antibodies directed
at different surface antigens (e.g., NMDAR, GABABR) are
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TABLE 1 | Laboratory techniques for the detection of neuronal cell-surface antibodies.
Number of IHC ICC of living CBA Commercial Sensitivity
patients neurons CBA and specificity
reported available
NMDAR >1000 Specific staining
pattern hippocampus
(AIE protocol)
(Dalmau et al., 2007) and
(Gresa-Arribas et al., 2014)
Surface labeling
of excitatory
synapses
(Hughes et al., 2010)
Fixed
(Dalmau et al., 2008)
and
(Gresa-Arribas et al., 2014)
Yes Sensitivity IHC:
CSF 100%, serum 92%
(Gresa-Arribas et al., 2014)
Sensitivity fixed CBA:
CSF 100%, serum 86%
(Gresa-Arribas et al., 2014)
Sensitivity IHC plus fixed CBA:
CSF 100%, serum 86%
(Gresa-Arribas et al., 2014)
Specificity IHC plus fixed CBA:
CSF 100%, serum 100%
(Gresa-Arribas et al., 2014)
LGI1 ∼250 Specific staining
pattern of
hippocampus
(AIE protocol)
(Lai et al., 2010)
Surface labeling
of neurons,
not further
specified
(Lai et al., 2010)
Fixed (with ADAM22/23
coexpression)
(Lai et al., 2010)
Fixed with added
transmembrane part
(van Sonderen et al., 2016c)
Live
(Irani et al., 2010a)
Yes Sensitivity IHC:
CSF 88%, serum 100%
(van Sonderen et al., 2016c)
Sensitivity fixed CBA:
CSF 53%, serum 100%
(van Sonderen et al., 2016c)
Caspr2 ∼100 Diffuse neuropil
staining
(AIE protocol)
(Lancaster et al., 2011a)
Surface labeling of
neurons, not further
specified
(Lancaster et al., 2011a)
Fixed
(Lancaster et al., 2011a)
Live
(Irani et al., 2012)
Yes Sensitivity fixed CBA:
CSF 100%, serum 100%
(van Sonderen et al., 2016a)
GlyR ∼75 Neuropil of
brainstem and
spinal cord
(PNS protocol)
(Carvajal-González et al., 2014)
Not published Live
(Carvajal-González et al.
2014)
No Sensitivity live CBA:
CSF: PERM 100%
(Carvajal-González et al., 2014),
SPS-spectrum 0%
(Martinez-Hernandez et al.,
2016),
serum: PERM 100%
(Carvajal-González et al.
2014)
Sensitivity fixed CBA:
Serum 92–94%
(disease controls)
(Martinez-Hernandez et al.,
2015)
(Martinez-Hernandez et al.
2016)
GABABR 67 Diffuse neuropil staining
(AIE protocol)
(Lancaster et al., 2010)
and (Höftberger et al., 2013)
Surface labeling of
neurons, not further
specified
(Lancaster et al., 2010)
Fixed
(Lancaster et al., 2010)
Yes Sensitivity fixed CBA:
CSF 100%, serum 67–93%
(Lancaster et al., 2010);
(Höftberger et al., 2013);
and (Jeffery et al., 2013)
DNER 65 PC cytoplasm,
punctate staining
of molecular
layer cerebellum
(PNS protocol)
(Graus et al., 1997)
and (de Graaff et al., 2012)
Surface labeling of
neurons overexpressing
DNER
(de Graaff et al., 2012)
Fixed
(de Graaff et al., 2012)
Live
(Greene et al., 2014)
Yes Sensitivity fixed CBA:
Serum 100%
(Probst et al., 2015)
Specificity fixed CBA:
Serum 100%
(Probst et al., 2015)
AMPAR 64 Diffuse neuropil
staining (AIE protocol)
(Lai et al., 2009)
Surface labeling of
excitatory synapses
(Lai et al., 2009)
Fixed (Lai et al., 2009)
and
(Höftberger et al., 2015)
Yes Specificity fixed CBA:
CSF 100%,
serum 70%
(Höftberger et al., 2015)
DPPX 28 Diffuse neuropil
staining
(AIE protocol)
Surface labeling of
both excitatory
and inhibitory
Fixed
(Boronat et al., 2013);
(Balint et al., 2014);
Yes Not available
(Continued)
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TABLE 1 | (Continued).
Number of IHC ICC of living CBA Commercial Sensitivity
patients neurons CBA and specificity
reported available
(Boronat et al., 2013);
(Balint et al., 2014);
and (Tobin et al., 2014)
synapses
(Piepgras et al., 2015)
and
(Tobin et al., 2014)
DopamineR∗ 26 Staining of
basal ganglia
(Dale et al., 2012)
Surface labeling
of neurons, not further
specified
(Dale et al., 2012)
Live
(Dale et al., 2012)
No Not available
mGluR1 16 PC cytoplasm,
molecular layer
cerebellum
(PNS protocol)
(Sillevis Smitt et al., 2000)
and
(Lopez-Chiriboga et al.,
2016)
Not published Fixed
(Lopez-Chiriboga et al.,
2016)
and (Iorio et al., 2013)
Yes Not available
IgLon5 10 Diffuse neuropil
staining (AIE protocol)
(Sabater et al., 2014)
Surface labeling
of neurons, not further
specified
(Sabater et al., 2014)
Live
(Sabater et al., 2014)
No Not available
mGluR5 3 Diffuse neuropil
staining (AIE protocol)
(Lancaster et al., 2011b)
Surface labeling
of neurons, not further
specified
(Lancaster et al., 2011b)
Fixed
(Lancaster et al., 2011b)
Yes Not available
IHC, Immunohistochemistry; ICC, Immunocytochemistry; CBA, Cell Based Assay; PC, Purkinje cell; PERM, Progressive encephalomyelitis with rigidity and myoclonus;
SPS, Stiff person syndrome; ∗Not confirmed by other laboratories.
indistinguishable (Dalmau et al., 2008; Lancaster et al., 2010).
More information on the specific subcellular localization of
the antigen could be determined by using co-staining with
(excitatory or inhibitory) synaptic markers. However, it needs to
be noted that binding of the patients antibodies to the antigen can
alter the protein’s localization. For the NMDA- and AMPAR it
has been shown that receptors move out of the synaptic area and
become internalized (Hughes et al., 2010; Mikasova et al., 2012;
Moscato et al., 2014; Peng et al., 2015). Therefore after surface
labeling such co-localization studies should be interpreted with
caution.
CELL BASED ASSAYS
In a CBA a recombinant antigen is expressed by mammalian
cells. The transfected cells are stained with patient serum or
CSF using IIF. When the patient sample contains antibodies
directed at this specific antigen, staining of the transfected cells is
enhanced when compared to non-transfected cells (Figure 1C).
In CBAs the antigen mostly maintains its tertiary structure
and the appropriate post-translational modifications. This allows
for the detection of antibodies directed at conformational
epitopes.
Commercial CBAs, as well as most research laboratories,
make use of human embryonic kidney (HEK) cells. HEK cells are
a cell line suitable for membrane protein expression (Chaudhary
et al., 2011). However, also HeLa or Chinese Hamster Ovary cells
can be used as these cell lines attach more tightly to the culture
plates than HEK cells and therefore wash off less easily during the
staining procedure.
Controversy exists on the timing of fixation during the
immunofluorescent staining procedure. With respect to the
anti-NR1 CBA, some laboratories perform surface staining
of live HEK cells with serum or CSF prior to fixation and
permeabilization (Irani et al., 2010b; Ramberger et al., 2015), as
in theory only relevant extracellular epitopes will be detected
(as described in ‘‘Immunocytochemistry on Living Primary
Hippocampal Neurons’’ Section). Other research groups fix and
permeabilize the cells before immunostaining, as is also used
in the commercial CBA. The only study to compare live vs.
fixed CBA in an unselected way found a higher sensitivity of the
fixed CBA (Gresa-Arribas et al., 2014), despite the theoretical
expectations of the opposite. In addition, it needs to be noted
that not all individual receptor subunits express equally well in
cell lines. Some need co-expression of other subunits, auxiliary
proteins or scaffolding molecules for proper receptor folding,
assembly, ER export and surface expression (Leite et al., 2008;
Irani et al., 2010b). This is especially important when performing
live CBAs in which the receptors need to be located in the plasma
membrane for antibodies to bind. It is therefore very well possible
that the optimal choice between live vs. fixed CBA might be
different for each receptor that is tested.
For both the fixed and live CBA one should also realize
that the presence of a large number of ion channels in the
plasma membrane for a longer period of time could lead to
excitotoxicity andmight require the addition of receptor blockers
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FIGURE 1 | Examples of staining patterns. (A) Immunohistochemistry (IHC) of rat brain slices using the autoimmune encephalitis (AIE) protocol. The left picture
shows neuropil staining of the hippocampus using anti-NMDA receptor (NMDAR) positive patient serum. The right picture shows staining with a healthy control
serum. Scale bars: 500 µm. (B) Live staining of cultured rat hippocampal neurons using anti-NMDAR positive patient or healthy control serum (green). The picture
shows a punctate staining pattern along the dendrites. Scale bars: 20 µm. (C) Examples of staining patterns of fixed Cell Based Assays (CBA) for anti-GABABR,
AMPAR and NMDAR antibodies. Transfected HeLa cells (green) show enhanced staining with patient serum (red) when compared to non-transfected cells and
healthy control serum. Scale bars: 20 µm. Adapted from: De Bruijn and Titulaer (2016), Figure 12.1.
(e.g., ketamine for NMDAR) to the culture medium (Irani et al.,
2010b; Ramberger et al., 2015)
Concerning the DNA constructs used for recombinant
antigen expression in CBAs it is important to keep in mind
that the addition of a molecular tag to a transmembrane protein
for visualization purposes can affect protein trafficking and
folding (Hughes et al., 2010). This could be overcome by
using an untagged version in combination with cytoplasmic
green fluorescent protein (GFP) to identify the transfected cells.
However, in this case a commercial antibody to the antigen needs
to be used to assess exact colocalization of antigen and patient
antibody.
Mostly CBAs are scored with a subjective visual scoring
system using epifluorescent microscopy. However, the staining
intensity can vary considerably within one coverslip and accurate
scoring depends heavily on the observers’ experience. For this
reason in most studies two independent blinded investigators
perform the scoring. Some laboratories use a semi-quantitative
scoring system ranging from 0 to 4 with an increasing strength
of fluorescence intensity (Leite et al., 2008). However the
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value of this type of semi-quantitative scoring has never been
validated. To get an idea of the antibody titres it is more
reliable to perform serial dilutions on IHC (Gresa-Arribas et al.,
2014).
Alternatively, the evaluation of CBAs using fluorescence-
activated cell sorting (FACS) is less dependent on experience. In
addition it could provide a quantitative method for determining
antibody titres without the need of testing serial dilutions. CBA
with FACS based scoring has been used for the detection of
anti-aquaporin-4 antibodies in neuromyelitis optica (De Vidi
et al., 2011) and anti-NMDAR (Amatoury et al., 2013). However,
only one study compared visual scoring of CBA with FACS
based analysis. This study showed lower sensitivity for anti-
NMDAR antibodies when FACS was used instead of visual
scoring (Ramberger et al., 2015).
Over the last years the sensitivity and specificity of CBAs
using serum or CSF has become increasingly clear (see Table 1).
Intrathecal antibody synthesis is high in anti-NMDA, -AMPA
and GABAB receptor encephalitis (Lai et al., 2009; Lancaster
et al., 2010; Dalmau et al., 2011), facilitating antibody detection
in CSF. For anti-NMDAR antibodies, a permeabilized CBA
has a sensitivity of 100% for CSF and 86% for serum (Gresa-
Arribas et al., 2014). For anti-AMPAR antibodies this is 100%
for CSF vs. 70% for serum (Höftberger et al., 2015), and for
anti-GABABR 100% for CSF and 67–93% for serum (Lancaster
et al., 2010; Höftberger et al., 2013; Jeffery et al., 2013). For
anti-LGI1 antibodies sensitivity on IHC is 88% and 100% for
CSF and serum respectively, whereas the commercial LGI1
CBA using CSF has only 53% sensitivity, probably reflecting
lower intrathecal antibody synthesis (van Sonderen et al.,
2016c). Special attention is required for patients undergoing
plasma exchange at the moment of serum assessment, as
antibodies may no longer be detectable in serum (Florance et al.,
2009).
Over the last years high throughput screenings have been
published, mainly in the field of psychiatry, in which the presence
of anti-neuronal surface antibodies is tested using CBA with
serum only. These studies have detected anti-NR1 antibodies
in up to 10% of neuropsychiatric disorders, but also in healthy
individuals (Zandi et al., 2011; Dahm et al., 2014; Hammer
et al., 2014). However, these studies were confusing due to
lumping of IgG with IgA/IgM antibody isotypes, incomplete
testing or selection bias. Only IgG subclass antibodies directed
at NR1 alone causes the disease described as anti-NMDAR
encephalitis. The clinical relevance of IgM and IgA antibodies
is so far unclear, as was also concluded from other articles
studying psychiatric populations (Steiner et al., 2013). Anti-
NMDAR encephalitis can present as an isolated first psychotic
episode (Kayser et al., 2013), although the presence of anti-
NMDAR encephalitis among first episode psychosis patients is
likely to be (less than) 1%. This chance quickly increases if
patients develop neurological symptoms or additional features
such as fever or autonomic dysfunction. In studies testing for
anti-NMDAR IgG in a purely psychiatric population using more
than one method (CBA combined with IHC or ICC of living
hippocampal neurons, or the combination of serum and CSF)
no patients with only psychiatric features and anti-NMDAR
encephalitis have been found (Masdeu et al., 2012; van Mierlo
et al., 2015). The low a priori chance in patients with psychiatric
disorders combined with a specificity of 97–99.4% for CBA
of serum (Gresa-Arribas et al., 2014) results in a post priori
chance of only 25–60% when testing serum only. These results
indicate that high throughput screening studies in a population
with low disease prevalence requires excellent specificity to be
of value. Combining CBA with IHC or live neuron staining
could for example increase the specificity (Gresa-Arribas et al.,
2014).
IMMUNOPRECIPITATION AND MASS
SPECTROMETRY ANALYSIS OF
MEMBRANE ANTIGENS
Some patients have a clinical phenotype strongly suggesting an
autoimmune etiology but test negative for all known surface
antigens. If IHC and live ICC provide a strong indication for
the presence of cell-surface antibodies one can try to identify
the molecular target of the antibodies in order to develop
a CBA. Classically, novel PNS antigens were identified using
cDNA expression libraries by phage display (Hufton et al.,
1999). Strikingly, only intracellular antigens with mostly linear
epitopes have been identified using this technique, indicating
that it is less suitable for conformational epitopes. Currently,
most novel surface antigens are identified by performing
immunoprecipitation with patient’s serum or CSF followed by
mass spectrometry analysis (IP-MS; Lai et al., 2009; Lancaster
et al., 2010; de Graaff et al., 2012; Boronat et al., 2013; Petit-
Pedrol et al., 2014; Sabater et al., 2014). Although in a seemingly
straightforward procedure many factors are complicating the
identification of a membrane antigen.
Firstly MS analysis is hampered by properties of the
membrane proteins itself. They are expressed relatively low
compared to cytosolic proteins. Due to their membrane
spanning hydrophobic domains membrane proteins aggregate
easily, leading to inefficient proteolytic cleavage. This leads
to underrepresentation of membrane proteins in the sample
(Helbig et al., 2010; Barrera and Robinson, 2011). Fractionation
of membrane preparations, synaptosome isolation or surface
biotinylation can be used to enrich (synaptic) membrane
proteins in the input material. In order to reduce the detection
of nonspecific cytosolic and nuclear proteins some labs
perform surface labeling of primary hippocampal neurons and
subsequently lyse the cells and precipitate IgG with the bound
antigen (Boronat et al., 2013).
Secondly membrane proteins have the tendency to misfold
when extracted by detergent. This leads to disruption of the
conformational epitope and reduced antibody binding. Special
attention is therefore required for the choice of detergent in
order to optimize solubilization. Which detergent is suitable
for membrane protein solubilization depends on the type of
membrane protein that needs to be extracted (Privé, 2007).
The fact that the membrane antigen is still unknown when
performing IP-MS severely hampers the choice of detergent. A
new amphipathic polymer that solubilizes membrane proteins in
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intact membrane patches might be a promising alternative (Dörr
et al., 2016).
In general CSF contains less antibodies than serum, both in
number and variety, and in case of intrathecal synthesis, the
relative amount of specific antibodies is higher. Therefore the
use of CSF in staining and immunoprecipitation is thought to
provide cleaner results. However, CSF is usually less readily
available than serum.
CONCLUSION AND RECOMMENDATIONS
The detection of synaptic cell-surface antibodies has significant
consequences for the treatment and follow-up of AIE patients. It
can confirm the autoimmune-mediated nature of the syndrome
and can provide a clue for a possible underlying tumor. In order
to successfully identify antibodies to surface antigens clinical
assessment and patient selection by an experienced clinician is
of key importance. For diagnostic purposes both serum and
CSF should be tested by a combination of IHC and CBA
to provide highest sensitivity and specificity. Live staining of
cultured hippocampal neurons is labor intensive. The neurons
used for diagnostic testing cannot be prepared beforehand and
cannot be stored. However, live ICC of neurons can provide
valuable additional information when the results from IHC and
CBA are inconclusive.
Samples selected for IP-MS need to show robust results on
both IHC and live ICC of hippocampal neurons. Preferentially
patients with a similar staining pattern and clinical phenotype
are grouped. If possible, two different serum samples from one
patient can be used to perform IP-MS. Comparing two lists of one
patient (or the lists of patients with a similar clinical phenotype
and/or similar staining pattern on IHC) could facilitate the
detection of novel antigens.
In the next years novel neuronal surface antigens will
be identified, most likely by screening cohorts of patients
with for example epilepsy or dementia. It is expected
that these yet unknown patients will phenotypically show
less encephalitis and more encephalopathy. As screening
becomes more extensive, careful evaluation of specificity
and pathogenicity of novel antibodies will be necessary.
Given the low frequency of occurrence of most of these
antibodies, meaningful clinical studies will require international
collaboration.
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